ArticleMolecular biotechnology2026
Cost-Effective Production of Biologically Active Leukemia Inhibitory Factor for Mouse Embryonic Stem Cell Culture.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Purification: Evolving Roles of Fusion Tags in Biotechnology.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Leukemia inhibitory factor (LIF), a glycoprotein in the interleukin-6 family, is essential for maintaining the pluripotency and self-renewal of mouse embryonic stem cells (mESCs) by activating the JAK/STAT pathway and preventing spontaneous differentiation. Despite its critical role in maintaining the undifferentiated state of ES cells, the high cost of commercially available LIF poses a considerable financial challenge for research laboratories. This financial strain can limit the accessibility and feasibility of high-quality stem cell research, thereby impacting the overall progress in this field. Here, we present an efficient and cost-effective method for recombinant expression and purification of biologically active, non-glycosylated mouse LIF in Escherichia coli, which retains full functionality in mESC culture. Utilizing an N-terminal glutathione S-transferase (GST) tag enhances the solubility of LIF, facilitating rapid purification via glutathione-agarose affinity chromatography. Following purification, LIF is cleaved from the GST tag using HRV 3C protease, resulting in a product ready for direct application in mESC culture. Homemade LIF (HM-LIF) prepared with this protocol effectively maintains mESCs in an undifferentiated state, showing comparable efficacy to commercial LIF. Furthermore, mESCs cultured with HM-LIF retain pluripotency and can differentiate into glutamatergic neurons. This streamlined approach significantly reduces the cost of mESC culture while providing a reliable, high-quality alternative to commercial LIF.
Indexed as
Identifiers
40629243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.